<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04090879</url>
  </required_header>
  <id_info>
    <org_study_id>CHRMS19-0129</org_study_id>
    <secondary_id>U54DA036114-06</secondary_id>
    <nct_id>NCT04090879</nct_id>
  </id_info>
  <brief_title>Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders</brief_title>
  <official_title>Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      While the prevalence of smoking in the United States general population has declined over the
      past 50 years, there has been little to no decline among people with mental health
      conditions. Affective Disorders (ADs) are the most common mental health conditions in the US,
      and over 40% of people with ADs are current smokers. A national policy of reducing the
      nicotine content of cigarettes has the potential to reduce tobacco use, dependence, and
      related adverse health outcomes. Controlled trials in psychiatrically-stable smokers have
      shown that reducing the nicotine content in cigarettes can reduce cigarettes per day (CPD),
      dependence and tobacco toxicant exposure, with few adverse consequences.

      The goal of the proposed trial is to experimentally model whether increasing the availability
      and appeal of an alternative, non-combusted source of nicotine (e-cigarettes) moderates the
      effect of altering the nicotine in cigarettes in smokers with ADs. Additionally,
      investigators will test whether allowing participants to personalize the flavor of the
      e-liquid alters any moderating effects their availability may have on tobacco cigarette
      smoking.

      Daily smokers with current ADs will be recruited at Brown University and the University of
      Vermont.

      Investigators will study two research cigarettes referred to here as Research Cigarette 1
      (RC1) and Research Cigarette 2 (RC2). One of these cigarettes will be a normal nicotine
      content cigarette and the other will be a reduced nicotine content cigarette. Investigators
      will study two e-cigarette conditions referred to here as E-Cigarette Condition 1 (EC1) and
      E-Cigarette Condition 2 (EC2). Both e-cigarette conditions will involve the same commercially
      available devices and same nicotine-containing e-liquid, but in one condition that e-liquid
      will be available only in tobacco flavor while in the other condition that e-liquid will be
      available in multiple flavors from which participants can choose based on personal taste
      preference. Participants will be assigned to one of the following four study conditions: (1)
      RC1 only; (2) RC2 only; (3) RC2 + EC1; (4) RC2 + EC2.

      Participants will be asked to use only their assigned study products for 16 weeks. Outcome
      measures include total CPD, cigarette demand assessed by behavioral economics-based purchase
      tasks, craving, withdrawal, psychiatric symptoms, breath carbon monoxide (CO), biomarkers of
      tobacco toxicant exposure, brain function and structure, and airway inflammation (fractional
      nitric oxide concentration in exhaled breath [FeNO]).
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    COVID19 pandemic
  </why_stopped>
  <start_date type="Actual">September 18, 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind dosing of tobacco cigarette nicotine levels.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cigarettes Per Day</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">232</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>RC 1 only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Research Cigarettes #1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RC 2 only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Research Cigarettes #2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RC 2 + EC 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Research Cigarettes #2 plus E-cigarettes #1 (participants receive tobacco flavor only)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RC 2 + EC 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Research Cigarettes #2 plus E-cigarettes #2 (participants can choose among varying flavors)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)</intervention_name>
    <description>1) Altering the nicotine content of the tobacco research cigarette</description>
    <arm_group_label>RC 1 only</arm_group_label>
    <arm_group_label>RC 2 + EC 1</arm_group_label>
    <arm_group_label>RC 2 + EC 2</arm_group_label>
    <arm_group_label>RC 2 only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>E-Cigarettes</intervention_name>
    <description>1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition</description>
    <arm_group_label>RC 2 + EC 1</arm_group_label>
    <arm_group_label>RC 2 + EC 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Between 21 years and 70 years old

          -  Must have current diagnosis of an Affective Disorder.

        Exclusion Criteria

          -  Being without an Affective Disorder

          -  Younger than 21 years old

          -  Older than 70 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer W Tidey, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>Jennifer Tidey</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Biomarkers of Exposure</keyword>
  <keyword>Compensatory Smoking</keyword>
  <keyword>Nicotine Dependence</keyword>
  <keyword>Reduced Nicotine Cigarettes</keyword>
  <keyword>Affective Disorders</keyword>
  <keyword>Tobacco Withdrawal</keyword>
  <keyword>Vulnerable Populations</keyword>
  <keyword>E-Cigarettes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

